Related references
Note: Only part of the references are listed.Treatment of Advanced Thyroid Cancer With Axitinib: Phase 2 Study With Pharmacokinetic/Pharmacodynamic and Quality-of-Life Assessments
Laura D. Locati et al.
CANCER (2014)
Sorafenib in radioactive iodine-refractory, locally advanced or metastatic differentiated thyroid cancer: a randomised, double-blind, phase 3 trial
Marcia S. Brose et al.
LANCET (2014)
Cabozantinib in Progressive Medullary Thyroid Cancer
Rossella Elisei et al.
JOURNAL OF CLINICAL ONCOLOGY (2013)
Axitinib in Metastatic Renal Cell Carcinoma: Results of a Pharmacokinetic and Pharmacodynamic Analysis
Brian I. Rini et al.
JOURNAL OF CLINICAL PHARMACOLOGY (2013)
Thyroid cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
F. Pacini et al.
ANNALS OF ONCOLOGY (2012)
Cancers with increasing incidence trends in the United States: 1999 through 2008
Edgar P. Simard et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2012)
Long-term analysis of the efficacy and tolerability of sorafenib in advanced radio-iodine refractory differentiated thyroid carcinoma: final results of a phase II trial
T. C. Schneider et al.
EUROPEAN JOURNAL OF ENDOCRINOLOGY (2012)
Effect of ketoconazole on the pharmacokinetics of axitinib in healthy volunteers
Yazdi K. Pithavala et al.
INVESTIGATIONAL NEW DRUGS (2012)
Vandetanib in Patients With Locally Advanced or Metastatic Medullary Thyroid Cancer: A Randomized, Double-Blind Phase III Trial
Samuel A. Wells et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
Vandetanib in locally advanced or metastatic differentiated thyroid cancer: a randomised, double-blind, phase 2 trial
Sophie Leboulleux et al.
LANCET ONCOLOGY (2012)
Analysis of the efficacy and toxicity of sorafenib in thyroid cancer: a phase II study in a UK based population
Merina Ahmed et al.
EUROPEAN JOURNAL OF ENDOCRINOLOGY (2011)
Influence of mild and moderate hepatic impairment on axitinib pharmacokinetics
Michael A. Tortorici et al.
INVESTIGATIONAL NEW DRUGS (2011)
Activity of XL184 (Cabozantinib), an Oral Tyrosine Kinase Inhibitor, in Patients With Medullary Thyroid Cancer
Razelle Kurzrock et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
Cancer mortality in Europe, 2000-2004, and an overview of trends since 1975
C. La Vecchia et al.
ANNALS OF ONCOLOGY (2010)
Effect of rifampin on the pharmacokinetics of Axitinib (AG-013736) in Japanese and Caucasian healthy volunteers
Y. K. Pithavala et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2010)
Population pharmacokinetic/pharmacodynamic modeling for the time course of tumor shrinkage by motesanib in thyroid cancer patients
Jian-Feng Lu et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2010)
Phase II Study of Daily Sunitinib in FDG-PET-Positive, Iodine-Refractory Differentiated Thyroid Cancer and Metastatic Medullary Carcinoma of the Thyroid with Functional Imaging Correlation
Laurie L. Carr et al.
CLINICAL CANCER RESEARCH (2010)
Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008
Jacques Ferlay et al.
INTERNATIONAL JOURNAL OF CANCER (2010)
Biomarkers as Predictors of Response to Treatment with Motesanib in Patients with Progressive Advanced Thyroid Cancer
Michael B. Bass et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2010)
Phase II Clinical Trial of Sorafenib in Metastatic Medullary Thyroid Cancer
Elaine T. Lam et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Efficacy of pazopanib in progressive, radioiodine-refractory, metastatic differentiated thyroid cancers: results of a phase 2 consortium study
Keith C. Bible et al.
LANCET ONCOLOGY (2010)
International patterns and trends in thyroid cancer incidence, 1973-2002
Briseis A. Kilfoy et al.
CANCER CAUSES & CONTROL (2009)
Phase II Study of Safety and Efficacy of Motesanib in Patients With Progressive or Symptomatic, Advanced or Metastatic Medullary Thyroid Cancer
Martin J. Schlumberger et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Phase II Trial of Sorafenib in Metastatic Thyroid Cancer
Richard T. Kloos et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Nonclinical Antiangiogenesis and Antitumor Activities of Axitinib (AG-013736), an Oral, Potent, and Selective Inhibitor of Vascular Endothelial Growth Factor Receptor Tyrosine Kinases 1, 2, 3
Dana D. Hu-Lowe et al.
CLINICAL CANCER RESEARCH (2008)
Axitinib is an active treatment for all histologic subtypes of advanced thyroid cancer: Results from a phase II study
Ezra E. W. Cohen et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Phase II trial of sorafenib in advanced thyroid cancer
Vandana Gupta-Abramson et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Motesanib diphosphate in progressive differentiated thyroid cancer
Steven I. Sherman et al.
NEW ENGLAND JOURNAL OF MEDICINE (2008)
New guidelines to evaluate the response to treatment in solid tumors
F Duffaud et al.
BULLETIN DU CANCER (2000)
New guidelines to evaluate the response to treatment in solid Tumors
P Therasse et al.
JOURNAL OF THE NATIONAL CANCER INSTITUTE (2000)
Share Paper
